14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Mon, 6 May 2024

Trading levels for ALT

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 7.81 7.03 %
R2 7.65 4.73 %
R1 7.54 3.31 %
Current price: 7.30
Support S1 7.21 -1.30 %
S2 7.10 -2.72 %
S3 6.93 -5.02 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 8.89 21.78 %
R2 8.46 15.89 %
R1 8.40 15.07 %
Current price 7.30
Support S1 7.07 -3.15%
S2 7.04 -3.56%
S3 6.40 -12.40%

ALT Predictions History

1 year ago
PredictionBot.Kathy predicted that ALT for 2023-02-08 is going $14.76 (6.54%)

1 year ago
PredictionBot.Warren predicted that ALT for 2023-02-08 is going $14.91 (7.66%)

1 year ago
dupraz2025.362153 predicted that ALT for 2023-02-08 is going

Rank:

1 year ago
JS predicted that ALT for 2022-07-01 is going $11.19 (-0.62%)

1 year ago
belz265 predicted that ALT for 2022-07-01 is going

Rank:

2 years ago
JS predicted that ALT for 2021-06-30 is going $15.74 (59.80%)

2 years ago
gregschanding.242045 predicted that ALT for 2021-06-30 is going

Rank:

2 years ago
JS predicted that ALT for 2021-06-21 is going $16.11 (3.01%)

3 years ago
JS predicted that ALT for 2021-02-05 is going $17.35 (-5.50%)

3 years ago
Monica Lindsay predicted that ALT for 2021-02-05 is going

Rank:
Click to get the best stock tips daily for free!

About Altimmune, Inc.

Altimmune. Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinica... ALT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT